A company that funds life-saving innovation in the healthcare sector.

415C

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access.

We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs.

Over the years, the 415 team has introduced over 25 breakthrough technologies to market and realized over 20 successful portfolio exits to-date, including Vesper Medical and Intact Vascular (both acquired by Philips), Claret Medical (acquired by Boston Scientific), ReCor Medical (acquired by Otsuka), CardiAQ Valve Technologies (acquired by Edwards), Atritech (acquired by Boston Scientific), CoreValve (acquired by Medtronic) and many more.

415 Capital

📢 Are you an organized, detail-oriented individual with exceptional multitasking abilities? Are you passionate about supporting a dynamic team in the fast-paced world of venture capital? If so, we have an exciting opportunity for you!
 
415 Capital is looking for an Executive Assistant (m/f/d) to join its MedTech Venture Capital team in the Munich area.
 
Visit our careers page at https://lnkd.in/dfu7D6jR to view the full job description and submit your application. We look forward to hearing from you!
 
Feel free to share this post or tag someone who might be interested.

415 Capital at the medtech strategist innovation summit in Dublin
#cardioandneurovascular is special

Congratulations to our portfolio company Aktiia for making it onto the Sifted 30 Leaderboard as one of Central Europe's fastest growing start-ups! 

No. 12: Aktiia

cc: Josep Solà Mattia Bertschi Daniel Graf 

🚀🚀🚀

We’re excited to share that Aktiia has achieved regulatory approval (CE mark) for their groundbreaking optical blood pressure (BP) monitor, which does not require calibration with a regular cuff. 👏 

Approval of Aktiia's CALFREE technology will allow it to offer integration of its medical-grade optical blood pressure monitoring to third-party companies developing consumer devices, such as smartwatches, smartphone cameras and smart bands.

We congratulate Aktiia and the entire team for achieving this significant milestone!

cc: Mattia Bertschi, Josep Solà

https://lnkd.in/eMnPs-VC

Congratulations to Ramon L. Varcoe, The Prince of Wales Hospital Sydney, and R3 Vascular Inc. on this great first case in Australia!

Last week, 415 Capital had the privilege of attending the Med-Tech World Summit in Malta.

Our principal, Linus Rieder, shared insights as a panelist, shedding light on the evolving landscape of venture capital in the med-tech industry. Additionally, he had the pleasure of engaging with entrepreneurs as a judge in the startup competition.

A special highlight: we are honored to have been recognized as the "Med-tech VC of the Year".

Thank you to everyone who has been part of our journey, and a big thank you to the organizers of Med-Tech World and Giovanni Lauricella and Lifeblood | Capital + Talent!

#MedTechWorldSummit #mtw2023  #venturecapital  #415Capital #mtw2023  #innovation  #medtech  #technology

415C

COM:415CAPITAL

415C

Financials Not Available